These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
351 related articles for article (PubMed ID: 26880993)
21. Mechanism and Method for Generating Tumor-Free iPS Cells Using Intronic MicroRNA miR-302 Induction. Lin SL; Ying SY Methods Mol Biol; 2018; 1733():265-282. PubMed ID: 29435940 [TBL] [Abstract][Full Text] [Related]
22. Comparison of Non-Coding RNAs in Exosomes and Functional Efficacy of Human Embryonic Stem Cell- versus Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Lee WH; Chen WY; Shao NY; Xiao D; Qin X; Baker N; Bae HR; Wei TT; Wang Y; Shukla P; Wu H; Kodo K; Ong SG; Wu JC Stem Cells; 2017 Oct; 35(10):2138-2149. PubMed ID: 28710827 [TBL] [Abstract][Full Text] [Related]
23. Mechanisms of the Metabolic Shift during Somatic Cell Reprogramming. Nishimura K; Fukuda A; Hisatake K Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31067778 [TBL] [Abstract][Full Text] [Related]
24. Challenges to the clinical application of pluripotent stem cells: towards genomic and functional stability. Fu X; Xu Y Genome Med; 2012; 4(6):55. PubMed ID: 22741526 [TBL] [Abstract][Full Text] [Related]
25. Application of induced pluripotent stem cell technology for the investigation of hematological disorders. Dolatshad H; Tatwavedi D; Ahmed D; Tegethoff JF; Boultwood J; Pellagatti A Adv Biol Regul; 2019 Jan; 71():19-33. PubMed ID: 30341008 [TBL] [Abstract][Full Text] [Related]
26. Metabolome Profiling of Partial and Fully Reprogrammed Induced Pluripotent Stem Cells. Park SJ; Lee SA; Prasain N; Bae D; Kang H; Ha T; Kim JS; Hong KS; Mantel C; Moon SH; Broxmeyer HE; Lee MR Stem Cells Dev; 2017 May; 26(10):734-742. PubMed ID: 28346802 [TBL] [Abstract][Full Text] [Related]
27. Age Is Relative-Impact of Donor Age on Induced Pluripotent Stem Cell-Derived Cell Functionality. Strässler ET; Aalto-Setälä K; Kiamehr M; Landmesser U; Kränkel N Front Cardiovasc Med; 2018; 5():4. PubMed ID: 29423397 [TBL] [Abstract][Full Text] [Related]
28. Reverse engineering human neurodegenerative disease using pluripotent stem cell technology. Liu Y; Deng W Brain Res; 2016 May; 1638(Pt A):30-41. PubMed ID: 26423934 [TBL] [Abstract][Full Text] [Related]
29. Current understanding and future perspectives of the roles of sirtuins in the reprogramming and differentiation of pluripotent stem cells. Hsu YC; Wu YT; Tsai CL; Wei YH Exp Biol Med (Maywood); 2018 Mar; 243(6):563-575. PubMed ID: 29557214 [TBL] [Abstract][Full Text] [Related]
30. Induced pluripotent stem cells from pigs and other ungulate species: an alternative to embryonic stem cells? Ezashi T; Telugu BP; Roberts RM Reprod Domest Anim; 2012 Aug; 47 Suppl 4():92-7. PubMed ID: 22827356 [TBL] [Abstract][Full Text] [Related]
31. The Immunogenicity and Immune Tolerance of Pluripotent Stem Cell Derivatives. Liu X; Li W; Fu X; Xu Y Front Immunol; 2017; 8():645. PubMed ID: 28626459 [TBL] [Abstract][Full Text] [Related]
32. Induced pluripotent stem cells (iPSCs)--a new era of reprogramming. Kang L; Kou Z; Zhang Y; Gao S J Genet Genomics; 2010 Jul; 37(7):415-21. PubMed ID: 20659705 [TBL] [Abstract][Full Text] [Related]
33. "Cutting the Mustard" with Induced Pluripotent Stem Cells: An Overview and Applications in Healthcare Paradigm. Behl T; Kaur I; Sehgal A; Singh S; Sharma N; Chigurupati S; Felemban SG; Alsubayiel AM; Iqbal MS; Bhatia S; Al-Harrasi A; Bungau S; Mostafavi E Stem Cell Rev Rep; 2022 Dec; 18(8):2757-2780. PubMed ID: 35793037 [TBL] [Abstract][Full Text] [Related]